Intellia Therapeutics granted China patent for CRISPR technology
Genome editing company Intellia Therapeutics has been granted a patent from China’s State Intellectual Property Office (SIPO) covering the CRISPR/Cas9 technology.
Yesterday, June 19, the company said that the patent includes claims covering methods for editing DNA in non-cellular and cellular settings, including in eukaryotic cells.
The company added that the patent also allows it to use the technology to produce medicines for treating disease.
Nessan Bermingham, CEO of Intellia, said: “SIPO’s decision further expands our IP portfolio, and is further global recognition that Jennifer Doudna, Emmanuelle Charpentier and their team are the pioneers in the application of CRISPR/Cas9 in all cell types.”
He added: “Intellia continues to build on preclinical work and to focus on the development of our pipeline of novel human therapeutics that will potentially transform the lives of patients with genetic diseases.”
Intellia has the rights to University of California (UC), Berkeley’s CRISPR IP, including the European and UK patents, for human therapeutic, prophylactic and palliative uses (including companion diagnostics), excluding anti-fungal and anti-microbial applications.
The company obtained these rights through a 2014 licence agreement with Caribou Biosciences, a company focusing on developing CRISPR/Cas9, which is the exclusive licensee of UC and the University of Vienna, two of the co-owners of the IP.
Today’s news:
Biopharma must target unpopularity, says Allergan
General Court to hear drug competition cases
Fed Circuit invalidates diagnostics patents
J&J reveals obesity and 3D printing collaborations
Merck granted its first CRISPR patent in Australia
Did you enjoy reading this story? Sign up to our free newsletters and get stories like this sent straight to your inbox.
